| ||
Oxford
Human TMEM16K (ANO10)
There are ten members of the TMEM16/Anoctamin family of proteins in mammals. Although the first members of this family to be discovered, TMEM16A and TMEM16B, have a calcium-regulated chloride channel function, subsequently other members of the family, such as TMEM16F, were found to have lipid scramblase activity combined with non-selective ion channel activity. TMEM16K was a relatively understudied member of the family despite the observation that mutations in TMEM16K have been linked to the genetic disease autosomal recessive spinocerebellar ataxia Type 10 (Also known as SCAR10 or ARCA3).
TWIK-Related Acid-Sensitive K+ Channel 1 (TASK1)
The TWIK related acid-sensitive K+ channel 1 (TASK-1) belongs to the family of two-pore domain potassium (K2P) channels. It regulates resting membrane potential and is expressed in cardiomyocytes, neurons and vascular smooth muscle cells.
Methylene-Tetrahydrofolate Reductase (MTHFR)
The folate and methionine cycles are essential metabolic pathways for life, involved respectively in DNA synthesis and generation of the ubiquitous methyl donor S-adenosylmethionine (SAM). The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) represents a key regulatory connection between these cycles, hence exerting a strong influence on an array of diseases. This TEP presents the first structures for any eukaryotic MTHFR, revealing a novel SAM-binding fold.
5'-Aminolevulinate synthase, erythoid-specific (ALAS2)
Erythorid specific 5’-Aminolevulinate synthase (ALAS2) catalyses the first and rate-determining step in haem biosynthesis during erythroid development.
Human Kalirin/RAC1 GEF/GTPase Complex
We have cloned, expressed, purified and crystallised the first DH GEF domain of Kalirin (gene: KALRN) in complex with RAC1 (gene: RAC1) as part of a programme to explore a new way of targeting GTPases. Fragment screening and X-ray crystallography has identified binders within the orthosteric binding site. A nucleotide exchange assay has been developed and GEF activity established.
New treatment could become first ever targeted therapy designed for ‘untreatable’ childhood brain cancer
A new type of drug that targets a genetic weakness in an untreatable childhood brain cancer could become the first ever treatment designed to target the disease.
The prototype treatment could also offer hope for patients with the rare and devastating ‘stone man syndrome’ – in which muscles and ligaments turn to bone.
Scientists at The Institute of Cancer Research, London, led research with an international team of colleagues, finding that the new drug class can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumours in mice.
Crystal structure of the kelch domain of human KLHL20 in complex with DAPK1 peptide
Crystal Structure of Ankyrin Repeat and Socs Box-Containing Protein 9 (Asb9) in Complex with Elonginb and Elonginc
Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology.
Annu. Rev. Pharmacol. Toxicol.. 2006 47:293-322 . doi: 10.1146/annurev.pharmtox.47.120505.105316
PMID: 17009925
Quantitative Analysis of Histone Demethylase Probes Using Fluorescence Polarization.
J. Med. Chem.. 2013 doi: 10.1021/jm3018628
PMID: 23725560